Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-ENSEMBLE: Ensartinib + Chemotherapy as Neoadjuvant Therapy for ALK+ NSCLC
NCT07354061Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response Rate at 9 weeks. Started Mar 2026; status: recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07354061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354061.